untitled h1
references

1. Mariotto AB, Rowland JH, Yabroff KR, et al. Long-term survivors of childhood cancers in the United States. *Cancer Epidemiol. Biomarkers Prev.* 2009;18(4):1033-1040.  
2. Weinstock H, Berman S, Cates W, Jr. Sexually transmitted diseases among American youth: incidence and prevalence estimates, 2000. *Perspect Sex Reprod Health.* 2004;36(1):6-10.  
3. Howlader N, Noone AM, Krapcho M, et al., eds. *SEER Cancer Statistics Review, 1975-2008* Bethesda, MD National Cancer Institute, based on November 2010 SEER data submission, posted to the SEER web site, April 15, 2011; 2011.  
4. Dunne EF, Unger ER, Sternberg M, et al. Prevalence of HPV infection among females in the United States. *JAMA.* 2007;297(8):813-819.  
5. Nielson CM, Flores R, Harris RB, et al. Human papillomavirus prevalence and type distribution in male anogenital sites and semen. *Cancer Epidemiol. Biomarkers Prev.* 2007;16(6):1107-1114.  
6. Leigh IM, Buchanan JA, Harwood CA, Cerio R, Storey A. Role of human papillomaviruses in cutaneous and oral manifestations of immunosuppression. *J. Acquir. Immune Defic. Syndr.* 1999;21 Suppl 1:S49-57.  
7. Ho GY, Burk RD, Klein S, et al. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. *J. Natl. Cancer Inst.* 1995;87(18):1365-1371.  
8. Giuliano AR, Tortolero-Luna G, Ferrer E, et al. Epidemiology of human papillomavirus infection in men, cancers other than cervical and benign conditions. *Vaccine.* 2008;26 Suppl 10:K17-28.  
9. Khan MJ, Castle PE, Lorincz AT, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. *J. Natl. Cancer Inst.* 2005;97(14):1072-1079.  
10. Centers for Disease Control and Prevention. *Human papillomavirus: HPV information for clinicians.*
Atlanta, GA: Centers for Disease Control and Prevention; 2006.  
11. Schlecht NF, Kulaga S, Robitaille J, et al. Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia. *JAMA.* 2001;286(24):3106-3114. 12. Freed GL, Derkay CS. Prevention of recurrent respiratory papillomatosis: role of HPV vaccination. Int. J.  
Pediatr. Otorhinolaryngol. 2006;70(10):1799-1803.  
13. Beutner KR, Reitano MV, Richwald GA, Wiley DJ. External genital warts: report of the American Medical Association Consensus Conference. AMA Expert Panel on External Genital Warts. *Clin. Infect. Dis.*
1998;27(4):796-806. 14. Sun XW, Kuhn L, Ellerbrock TV, Chiasson MA, Bush TJ, Wright TC, Jr. Human papillomavirus infection in women infected with the human immunodeficiency virus. *N. Engl. J. Med.* 1997;337(19):1343-1349.  
15. Petry KU, Scheffel D, Bode U, et al. Cellular immunodeficiency enhances the progression of human papillomavirus-associated cervical lesions. *Int. J. Cancer.* 1994;57(6):836-840.  
16. Chaturvedi AK, Madeleine MM, Biggar RJ, Engels EA. Risk of human papillomavirus-associated cancers among persons with AIDS. *J. Natl. Cancer Inst.* 2009;101(16):1120-1130.  
17. Rose B, Wilkins D, Li W, et al. Human papillomavirus in the oral cavity of patients with and without renal transplantation. *Transplantation.* 2006;82(4):570-573.  
18. Malouf MA, Hopkins PM, Singleton L, Chhajed PN, Plit ML, Glanville AR. Sexual health issues after lung transplantation: importance of cervical screening. *J. Heart Lung Transplant.* 2004;23(7):894-897.  
19. Kosmidis S, Baka M, Bouhoutsou D, et al. Longitudinal assessment of immunological status and rate of immune recovery following treatment in children with ALL. *Pediatr Blood Cancer.* 2008;50(3):528-532.  
20. Fioredda F, Cavillo M, Banov L, Plebani A, Timitilli A, Castagnola E. Immunization after the elective end of antineoplastic chemotherapy in children. *Pediatr Blood Cancer.* 2009;52(2):165-168.  
21. Jaffe D, Papadopoulos EB, Young JW, et al. Immunogenicity of recombinant hepatitis B vaccine (rHBV)
in recipients of unrelated or related allogeneic hematopoietic cell (HC) transplants. *Blood.* 2006;108(7):24702475.  
22. Katz RL, Veanattukalathil S, Weiss KM. Human papillomavirus infection and neoplasia of the cervix and anogenital region in women with Hodgkin's disease. *Acta Cytol.* 1987;31(6):845-854. 23. Bhatia S, Louie AD, Bhatia R, et al. Solid cancers after bone marrow transplantation. *J. Clin. Oncol.*
2001;19(2):464-471. 24. Socie G, Curtis RE, Deeg HJ, et al. New malignant diseases after allogeneic marrow transplantation for childhood acute leukemia. *J. Clin. Oncol.* 2000;18(2):348-357.  
25. Sasadeusz J, Kelly H, Szer J, Schwarer AP, Mitchell H, Grigg A. Abnormal cervical cytology in bone Page 46 of 52 marrow transplant recipients. *Bone Marrow Transplant.* 2001;28(4):393-397.  
26. Daneshpouy M, Socie G, Clavel C, et al. Human papillomavirus infection and anogenital condyloma in bone marrow transplant recipients. *Transplantation.* 2001;71(1):167-169.  
27. Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. *N. Engl. J. Med.* 2007;356(19):1928-1943.  
28. Merck & Co. I. *Gardasil [Human papillomavirus Quadrivalent (types 6, 11, 16, and 18) vaccine,* recombinant] full prescribing information updated December 2010. Whitehouse Station, NJ: Merck & Co., Inc.;
2010.  
29. Villa LL, Ault KA, Giuliano AR, et al. Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. *Vaccine.* 2006;24(27-28):5571-5583.  
30. Block SL, Nolan T, Sattler C, et al. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. *Pediatrics.* 2006;118(5):2135-2145.  
31. Reisinger KS, Block SL, Lazcano-Ponce E, et al. Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial. *Pediatr. Infect. Dis. J.* 2007;26(3):201-209.  
32. Giuliano AR, Palefsky JM, Goldstone S, et al. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. *N. Engl. J. Med.* 2011;364(5):401-411.  
33. Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. *N. Engl. J. Med.* 2003;348(6):518-527.  
34. Wiley DJ, Douglas J, Beutner K, et al. External genital warts: diagnosis, treatment, and prevention. *Clin.*
Infect. Dis. 2002;35(Suppl 2):S210-224.  
35. Joura EA, Giuliano AR, Iversen OE, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. *N. Engl. J. Med.* 2015;372(8):711-723.  
36. Van Damme P, Olsson SE, Block S, et al. Immunogenicity and Safety of a 9-Valent HPV Vaccine.  
Pediatrics. 2015;136(1):e28-39.  
37. Petrosky E, Bocchini JA, Jr., Hariri S, et al. Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices. *MMWR. Morb. Mortal.* Wkly. Rep. 2015;64(11):300-304.  
38. Launay O, van der Vliet D, Rosenberg AR, et al. Safety and immunogenicity of 4 intramuscular double doses and 4 intradermal low doses vs standard hepatitis B vaccine regimen in adults with HIV-1: a randomized controlled trial. *JAMA.* 2011;305(14):1432-1440.  
39. Tielemans CL, Vlasak J, Kosa D, et al. Immunogenicity and safety of an investigational AS02(v)- adjuvanted hepatitis B vaccine in patients with renal insufficiency who failed to respond or to maintain antibody levels after prior vaccination: results of two open, randomized, comparative trials. *Vaccine.* 2011;29(6):1159-1166.  
40. Dorell C, Stokley S, Yankey D, Cohn A, Markowitz L. National, state, and local area vaccination coverage among adolescents aged 13-17 years --- United States, 2009. *MMWR. Morb. Mortal. Wkly. Rep.*
2010;59(32):1018-1023.  
41. Tjiong MY, Out TA, Ter Schegget J, Burger MP, Van Der Vange N. Epidemiologic and mucosal immunologic aspects of HPV infection and HPV-related cervical neoplasia in the lower female genital tract: a review. *Int J Gynecol Cancer.* 2001;11(1):9-17.  
42. Centers for Disease Control and Prevention. *The Pink Book: Epidemiology and prevention of vaccine* preventable diseases. 12th ed. Atlanta, GA: Centers for Disease Control and Prevention; 2011.  
43. Daling JR, Sherman KJ. Relationship between human papillomavirus infection and tumours of anogenital sites other than the cervix. *IARC Sci. Publ.* 1992(119):223-241.  
44. Kreimer AR, Clifford GM, Boyle P, Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. *Cancer Epidemiol. Biomarkers Prev.* 2005;14(2):467475.  
45. Parkin DM, Bray F. Chapter 2: The burden of HPV-related cancers. *Vaccine.* 2006;24 Suppl 3:S3/11-25.  
46. Manhart LE, Holmes KK, Koutsky LA, et al. Human papillomavirus infection among sexually active young women in the United States: Implications for developing a vaccination strategy. *Sex. Transm. Dis.*
2006;33(8):502-508. 47. Tarkowski TA, Koumans EH, Sawyer M, et al. Epidemiology of human papillomavirus infection and abnormal cytologic test results in an urban adolescent population. *J. Infect. Dis.* 2004;189(1):46-50.  
48. Winer RL, Lee SK, Hughes JP, Adam DE, Kiviat NB, Koutsky LA. Genital human papillomavirus infection:
incidence and risk factors in a cohort of female university students. *Am. J. Epidemiol.* 2003;157(3):218-226.  
49. Revzina NV, Diclemente RJ. Prevalence and incidence of human papillomavirus infection in women in the USA: a systematic review. *Int. J. STD AIDS.* 2005;16(8):528-537.  
50. Insinga RP, Dasbach EJ, Elbasha EH. Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US: analytic framework and review of the literature.  
Pharmacoeconomics. 2005;23(11):1107-1122. 51. Palefsky JM, Holly EA. Chapter 6: Immunosuppression and co-infection with HIV. *J. Natl. Cancer Inst.*
Monogr. 2003(31):41-46.  
52. Stockfleth E, Nindl I, Sterry W, Ulrich C, Schmook T, Meyer T. Human papillomaviruses in transplantassociated skin cancers. *Dermatol. Surg.* 2004;30(4 Pt 2):604-609.  
53. Adami J, Gabel H, Lindelof B, et al. Cancer risk following organ transplantation: a nationwide cohort study in Sweden. *Br. J. Cancer.* 2003;89(7):1221-1227.  
54. Roka S, Rasoul-Rockenschaub S, Roka J, Kirnbauer R, Muhlbacher F, Salat A. Prevalence of anal HPV
infection in solid-organ transplant patients prior to immunosuppression. *Transpl. Int.* 2004;17(7):366-369.  
55. Patel HS, Silver AR, Northover JM. Anal cancer in renal transplant patients. *Int. J. Colorectal Dis.*
2007;22(1):1-5.  
56. Brown MR, Noffsinger A, First MR, Penn I, Husseinzadeh N. HPV subtype analysis in lower genital tract neoplasms of female renal transplant recipients. *Gynecol. Oncol.* 2000;79(2):220-224.  
57. Wright TC, Jr., Ellerbrock TV, Chiasson MA, Van Devanter N, Sun XW. Cervical intraepithelial neoplasia in women infected with human immunodeficiency virus: prevalence, risk factors, and validity of Papanicolaou smears. New York Cervical Disease Study. *Obstet. Gynecol.* 1994;84(4):591-597.  
58. Palefsky JM, Minkoff H, Kalish LA, et al. Cervicovaginal human papillomavirus infection in human immunodeficiency virus-1 (HIV)-positive and high-risk HIV-negative women. *J. Natl. Cancer Inst.* 1999;91(3):226236. 59. Palefsky JM, Gillison ML, Strickler HD. Chapter 16: HPV vaccines in immunocompromised women and men. *Vaccine.* 2006;24 Suppl 3:S3/140-146.  
60. Piketty C, Darragh TM, Da Costa M, et al. High prevalence of anal human papillomavirus infection and anal cancer precursors among HIV-infected persons in the absence of anal intercourse. *Ann. Intern. Med.*
2003;138(6):453-459.  
61. Frisch M, Biggar RJ, Goedert JJ. Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. *J. Natl. Cancer Inst.*
2000;92(18):1500-1510.  
62. Slivnick DJ, Ellis TM, Nawrocki JF, Fisher RI. The impact of Hodgkin's disease on the immune system.  
Semin. Oncol. 1990;17(6):673-682.  
63. Quayle AJ. The innate and early immune response to pathogen challenge in the female genital tract and the pivotal role of epithelial cells. *J. Reprod. Immunol.* 2002;57(1-2):61-79.  
64. Fujimura M, Ostrow RS, Okagaki T. Implication of human papillomavirus in postirradiation dysplasia.  
Cancer. 1991;68(10):2181-2185.  
65. Barzon L, Pizzighella S, Corti L, Mengoli C, Palu G. Vaginal dysplastic lesions in women with hysterectomy and receiving radiotherapy are linked to high-risk human papillomavirus. *J. Med. Virol.*
2002;67(3):401-405.  
66. Seidman JD, Kumar D, Cosin JA, Winter WE, 3rd, Cargill C, Boice CR. Carcinomas of the female genital tract occurring after pelvic irradiation: a report of 15 cases. *Int. J. Gynecol. Pathol.* 2006;25(3):293-297. 67. Alexander KA, Dempsey AF, Gillison ML, Palefsky J. HPV vaccines. *Infect Dis Child.* 2010:14-21.  
68. Villa LL, Costa RL, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. *Lancet Oncol.* 2005;6(5):271-278.  
69. Merck & Co. I. *Gardasil 9 (Human Papillomavirus 9-valent Vaccine, Recombinant) Prescribing* Information. Whitehouse Station, NJ: Merck & Co., Inc.; 2015. 70. Food and Drug Administration. *Gardasil 9 Summary Basis of Regulatory Action.* Silver Spring, MD: U. S.  
Food and Drug Administration; 2015. 71. Giuliano AR, Lazcano-Ponce E, Villa L, et al. Impact of baseline covariates on the immunogenicity of a quadrivalent (types 6, 11, 16, and 18) human papillomavirus virus-like-particle vaccine. *J. Infect. Dis.*
2007;196(8):1153-1162. 72. Levin MJ, Moscicki AB, Song LY, et al. Safety and immunogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine in HIV-infected children 7 to 12 years old. *J. Acquir. Immune* Defic. Syndr. 2010;55(2):197-204.  
73. Block SL, Brown DR, Chatterjee A, et al. Clinical trial and post-licensure safety profile of a prophylactic human papillomavirus (types 6, 11, 16, and 18) l1 virus-like particle vaccine. *Pediatr. Infect. Dis. J.* 2010;29(2):95101.  
74. Slade BA, Leidel L, Vellozzi C, et al. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. *JAMA.* 2009;302(7):750-757.  
75. Ljungman P, Engelhard D, de la Camara R, et al. Vaccination of stem cell transplant recipients:
recommendations of the Infectious Diseases Working Party of the EBMT. *Bone Marrow Transplant.*
2005;35(8):737-746.  
76. Zengin E, Sarper N. Humoral immunity to diphtheria, tetanus, measles, and hemophilus influenzae type b in children with acute lymphoblastic leukemia and response to re-vaccination. *Pediatr Blood Cancer.*
2009;53(6):967-972.  
77. Zignol M, Peracchi M, Tridello G, et al. Assessment of humoral immunity to poliomyelitis, tetanus, hepatitis B, measles, rubella, and mumps in children after chemotherapy. *Cancer.* 2004;101(3):635-641.  
78. Esposito S, Cecinati V, Brescia L, Principi N. Vaccinations in children with cancer. *Vaccine.*
2010;28(19):3278-3284.  
79. Fallen PR, McGreavey L, Madrigal JA, et al. Factors affecting reconstitution of the T cell compartment in allogeneic haematopoietic cell transplant recipients. *Bone Marrow Transplant.* 2003;32(10):1001-1014.  
80. Kroon FP, van Dissel JT, Rijkers GT, Labadie J, van Furth R. Antibody response to Haemophilus influenzae type b vaccine in relation to the number of CD4+ T lymphocytes in adults infected with human immunodeficiency virus. *Clin. Infect. Dis.* 1997;25(3):600-606.  
81. Avanzini MA, Carra AM, Maccario R, et al. Antibody response to pneumococcal vaccine in children receiving bone marrow transplantation. *J. Clin. Immunol.* 1995;15(3):137-144.  
82. Mustafa MM, Buchanan GR, Winick NJ, et al. Immune recovery in children with malignancy after cessation of chemotherapy. *J. Pediatr. Hematol. Oncol.* 1998;20(5):451-457.  
83. Alanko S, Pelliniemi TT, Salmi TT. Recovery of blood B-lymphocytes and serum immunoglobulins after chemotherapy for childhood acute lymphoblastic leukemia. *Cancer.* 1992;69(6):1481-1486.  
84. Rizzo JD, Wingard JR, Tichelli A, et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation: joint recommendations of the European Group for Blood and Marrow Transplantation, the Center for International Blood and Marrow Transplant Research, and the American Society of Blood and Marrow Transplantation. *Biol. Blood Marrow Transplant.* 2006;12(2):138-151.  
85. Johnston BL, Conly JM. Immunization for bone marrow transplant recipients. *Can J Infect Dis.*
2002;13(6):353-357.  
86. Kahn JA, Rosenthal SL, Jin Y, Huang B, Namakydoust A, Zimet GD. Rates of human papillomavirus vaccination, attitudes about vaccination, and human papillomavirus prevalence in young women. *Obstet. Gynecol.*
2008;111(5):1103-1110.  
87. CDC. Vaccination coverage among adolescents aged 13-17 years - United States, 2007. MMWR. Morb.  
Mortal. Wkly. Rep. 2008;57(40):1100-1103.  
88. U. S. Department of Health and Human Services. Objective 14-27: increase routine vaccination coverage levels for adolescents. Healthy People 2010 (conference ed, in 2 vols). . Washington, DC: US Department of Health and Human Services; Available at http://www.healthypeople.gov/document/html/objectives/14-27.htm; 2000.  
89. Benard VB, Johnson CJ, Thompson TD, et al. Examining the association between socioeconomic status and potential human papillomavirus-associated cancers. *Cancer.* 2008;113(10 Suppl):2910-2918.  
90. Yeazel MW, Oeffinger KC, Gurney JG, et al. The cancer screening practices of adult survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. *Cancer.* 2004;100(3):631-640.  
91. Gurney JG, Krull KR, Kadan-Lottick N, et al. Social outcomes in the Childhood Cancer Survivor Study cohort. *J. Clin. Oncol.* 2009;27(14):2390-2395.  
92. Brewer NT, Fazekas KI. Predictors of HPV vaccine acceptability: a theory-informed, systematic review.  
Prev. Med. 2007;45(2-3):107-114.  
93. Constantine NA, Jerman P. Acceptance of human papillomavirus vaccination among Californian parents of daughters: a representative statewide analysis. *J. Adolesc. Health.* 2007;40(2):108-115.  
94. Mays RM, Sturm LA, Zimet GD. Parental perspectives on vaccinating children against sexually transmitted infections. *Soc. Sci. Med.* 2004;58(7):1405-1413.  
95. Rosenthal SL, Rupp R, Zimet GD, et al. Uptake of HPV vaccine: demographics, sexual history and values, parenting style, and vaccine attitudes. *J. Adolesc. Health.* 2008;43(3):239-245.  
96. Dempsey AF, Zimet GD, Davis RL, Koutsky L. Factors that are associated with parental acceptance of human papillomavirus vaccines: a randomized intervention study of written information about HPV. *Pediatrics.*
2006;117(5):1486-1493.  
97. Jain N, Euler GL, Shefer A, Lu P, Yankey D, Markowitz L. Human papillomavirus (HPV) awareness and vaccination initiation among women in the United States, National Immunization Survey-Adult 2007. *Prev. Med.*
2009;48(5):426-431.  
98. Ragin C, Edwards R, Jones J, et al. Knowledge about human papillomavirus and the HPV vaccine - a survey of the general population. *Infect. Agent Cancer.* 2009;4:S10.  
99. Boehner CW, Howe SR, Bernstein DI, Rosenthal SL. Viral sexually transmitted disease vaccine acceptability among college students. *Sex. Transm. Dis.* 2003;30(10):774-778.  
100. Kahn JA, Rosenthal SL, Jin Y, et al. 32: Vaccine-type HPV infection and post-licensure attitudes about HPV vaccination in young women. Paper presented at: Society for Adolescent Medicine2008; Greensboro, North Carolina.  
101. Zimet GD, Fortenberry JD, Blythe MJ. Adolescents' attitudes about HIV immunization. *J. Pediatr. Psychol.*
1999;24:67-75.  
102. Rosenthal SL, Kottenhahn RK, Biro FM, Succop PA. Hepatitis B vaccine acceptance among adolescents and their parents. *J. Adolesc. Health.* 1995;17:248-254.  
103. Zimet GD, Mays RM, Winston Y, Kee R, Dickes J, Su L. Acceptability of human papillomavirus immunization. *J Womens Health Gend Based Med.* 2000;9(1):47-50.  
104. Zimet GD, Blythe MJ, Fortenberry JD. Vaccine characteristics and acceptability of HIV immunization among adolescents. *Int. J. STD AIDS.* 2000;11(3):143-149.  
105. Gamble HL, Klosky JL, Parra GR, Randolph ME. Factors influencing familial decision-making regarding human papillomavirus vaccination. *J. Pediatr. Psychol.* 2010;35(7):704-715.  
106. Gerend MA, Lee SC, Shepherd JE. Predictors of human papillomavirus vaccination acceptability among underserved women. *Sex. Transm. Dis.* 2007;34(7):468-471.  
107. Davis K, Dickman ED, Ferris D, Dias JK. Human papillomavirus vaccine acceptability among parents of 10- to 15-year-old adolescents. *J Low Genit Tract Dis.* 2004;8(3):188-194.  
108. Marlow LA, Waller J, Wardle J. Parental attitudes to pre-pubertal HPV vaccination. *Vaccine.*
2007;25(11):1945-1952.  
109. Kahn JA, Rosenthal SL, Hamann T, Bernstein DI. Attitudes about human papillomavirus vaccine in young women. *Int. J. STD AIDS.* 2003;14(5):300-306.  
110. de Visser R, McDonnell E. Correlates of parents' reports of acceptability of human papilloma virus vaccination for their school-aged children. *Sex Health.* 2008;5(4):331-338.  
111. Slomovitz BM, Sun CC, Frumovitz M, et al. Are women ready for the HPV vaccine? *Gynecol. Oncol.*
2006;103(1):151-154.  
112. Brabin L, Roberts SA, Farzaneh F, Kitchener HC. Future acceptance of adolescent human papillomavirus vaccination: a survey of parental attitudes. *Vaccine.* 2006;24(16):3087-3094.  
113. Kahn JA, Zimet GD, Bernstein DI, et al. Pediatricians' intention to administer human papillomavirus vaccine: the role of practice characteristics, knowledge, and attitudes. *J. Adolesc. Health.* 2005;37(6):502-510.  
114. Kahn JA, Rosenthal SL, Tissot AM, Bernstein DI, Wetzel C, Zimet GD. Factors influencing pediatricians' intention to recommend human papillomavirus vaccines. *Ambul Pediatr.* 2007;7(5):367-373. 115. Ziv A, Boulet JR, Slap GB. Utilization of physician offices by adolescents in the United States. *Pediatrics.*
1999;104(1 Pt 1):35-42.  
116. Pizzo PA, Poplack DG, eds. *Principles and practice of pediatric oncology.* 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2011.  
117. Becker M. The Health Belief Model and personal health behavior. In: Becker M, ed. *Health education* monographs. San Francisco: Society for Public Health Education; 1974:324-473. 118. Rosenstock IM, Strecher VJ, Becker MH. Social learning theory and the Health Belief Model. *Health* Educ. Q. 1988;15(2):175-183.  
119. Ajzen I. The theory of planned behavior. *Organ. Behav. Hum. Decis. Process.* 1991;50(2):179-211.  
120. Rimer BK, Glanz K. Theory at a glance: A guide for health promotion practice (Second edition). National Institutes of Health, National Cancer Institute; 2005: http://www.cancer.gov/PDF/481f5d53-63df-41bc-bfaf5aa48ee1da4d/TAAG3.pdf. Accessed July 27, 2008.  
121. Werba BE, Hobbie W, Kazak AE, Ittenbach RF, Reilly AF, Meadows AT. Classifying the intensity of pediatric cancer treatment protocols: the intensity of treatment rating scale 2.0 (ITR-2). *Pediatr Blood Cancer.*
2007;48(7):673-677. 122. CDC. Quadrivalent human papillomavirus vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). *Morbidity and Mortality Weekly Report.* 2007;56(No. RR-2):1-26.  
123. Cox DS, Cox AD, Sturm L, Zimet G. Behavioral interventions to increase HPV vaccination acceptability among mothers of young girls. *Health Psychol.* 2010;29(1):29-39.  
124. Cox MF, Fasolino TK, Tavakoli AS. Factor analysis and psychometric properties of the MotherAdolescent Sexual Communication (MASC) instrument for sexual risk behavior. *J. Nurs. Meas.* 2008;16(3):171183.  
125. Miller KS, Kotchick BA, Dorsey S, Forehand R, Ham AY. Family communication about sex: what are parents saying and are their adolescents listening? *Fam. Plann. Perspect.* 1998;30(5):218-222, 235.  
126. Dutra R, Miller KS, Forehand R. The process and content of sexual communication with adolescents in two-parent families: Associations with sexual risk-taking behavior. *AIDS and Behavior.* 1999;3(1):59-66.  
127. Gomez CA, Marin BV. Gender, culture, and power: Barriers to safe sex. *J Sex Research.* 1996;33(4):355362.  
128. Furman W. Parent-child relationship questionnaire. In: Perlmutter BF, Touliatos J, Holden GW, eds.  
Handbook of family measurement techniques. Thousand Oaks, CA: Sage; 2001:285-289.  
129. Donenberg G, Baker BL. Family impact questionnaire. In: Perlmutter BF, Touliatos J, Holden GW, eds.  
Handbook of family measurement techniques. Thousand Oaks, CA: Sage; 2001:447-450.  
130. Kelly JA, Murphy DA, Bahr GR, et al. AIDS/HIV risk behavior among the chronic mentally ill. A. J.  
Psychiatry. 1992;149(7):886-889.  
131. Kelly JA, McAuliffe TL, Sikkema KJ, et al. Reduction in risk behavior among adults with severe mental illness who learned to advocate for HIV prevention. *Psychiatr. Serv.* 1997;48(10):1283-1288.  
132. Children's Oncology Group. Long-term follow-up guidelines for survivors of childhood, adolescent, and young adult cancers, version 3.0. Arcadia, CA: Children's Oncology Group; 2008.  
133. Opalka D, Lachman CE, MacMullen SA, et al. Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16, and 18 by a multiplexed luminex assay.  
Clin. Diagn. Lab. Immunol. 2003;10(1):108-115.  
134. Smith JF, Kowalski R, Esser MT, Brown MJ, Bryan JT. Evolution of type-specific immunoassays to evaluate the functional immune response to Gardasil: a vaccine for human papillomavirus types 16, 18, 6 and 11.  
Hum Vaccin. 2008;4(2):134-142.  
135. Neuzil KM, Canh do G, Thiem VD, et al. Immunogenicity and reactogenicity of alternative schedules of HPV vaccine in Vietnam: a cluster randomized noninferiority trial. *JAMA.* 2011;305(14):1424-1431. 136. Korn EL, Freidlin B. Conditional power calculations for clinical trials with historical controls. *Stat. Med.*
2006;25(17):2922-2931.  
137. Miettinen O, Nurminen M. Comparative analysis of two rates. *Stat. Med.* 1985;4(2):213-226.  
138. Wang ZH, Kjellberg L, Abdalla H, et al. Type specificity and significance of different isotypes of serum antibodies to human papillomavirus capsids. *J. Infect. Dis.* 2000;181(2):456-462.  
139. Brown DR, Garland SM, Ferris DG, et al. The humoral response to Gardasil(R) over four years as defined by Total IgG and competitive Luminex immunoassay. *Hum Vaccin.* 2011;7(2).  
APPENDICES
untitled h1
appendix content

1 Medical Record Review Form 2 Intensity of Treatment Rating Scale 2.0 3 HPV Vaccination Survey - Parent/caregiver version - male patient (age 9-17) - Parent/caregiver version - female patient (age 9-17)
- Patient version - male (age 18-26) - Patient version - female (age 18-26)
4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20  
| Thank You Letter - Survey  Sample Patient Recruitment Materials  Appointment Reminder Letter - Vaccine  Children's Oncology Group Cancer Treatment Summary Form  Vaccine Visit Form  Month 7 Visit Form (Follow-Up #1)  Premature Study Discontinuation (PSD) Form  Blood Specimen Collection, Processing, Storage, and Shipping Guidelines  Sample CDC Teaching Tools: Human Papillomavirus  Sample VIS: HPV vaccine  Vaccine Report Card (7- and 14-day versions)  Adverse Events/Research-Related Problems Reporting Form (AERF)  Month 24 Visit Form (Follow-Up #2)  Thank You Letter - Vaccine  VAERS Reporting Form  PMT Report  Summary of Potential Adverse Events/Research-Related Problems Reporting  Requirements   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|